Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 12/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371133 | 0.88 | CTSK (0.44) | CTSKPPARAPPARGHTTOPRM1 | |
| SCHEMBL346061 | 0.86 | CTSK (0.46) | CTSKCTSLHTT | |
| SCHEMBL346550 | 0.80 | CTSL (0.54) | CTSKCTSLCTSSPPARAPPARG | |
| SCHEMBL346551 | 0.80 | CTSL (0.54) | CTSKCTSLCTSSPPARAPPARG | |
| SCHEMBL9830861 | 0.78 | CTSK (0.48) | CTSKHTTOPRM1 | |
| SCHEMBL9830863 | 0.78 | CTSK (0.48) | CTSKHTTOPRM1 | |
| SCHEMBL347305 | 0.77 | LPAR1 (0.43) | CTSKOPRM1 | |
| SCHEMBL346994 | 0.76 | LMNA (0.43) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL345954 | 0.76 | CTSK (0.46) | CTSKHTTOPRM1 | |
| Bromide SCHEMBL1200370 | 0.75 | LMNA (0.42) | CTSKCTSSPPARAPPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TACR3 1751/4885CTSK 87/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.